A dopam/ine D 2 receptor mutant capable of G protein- mediated signaling but deficient in arrestin binding

Molecular Pharmacology

Volumn 75, Issue 1, 2009, Pages 113-123

  Lan, Hongxiang ^a   Liu, Yong ^a   Bell, Michal I ^a   Gurevich, Vsevolod V ^c   Neve, Kim A ^a,b,d  

^a Department of Behavioral Neuroscience ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLUTATHIONE TRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; RETINA S ANTIGEN; CYCLIC AMP; DOPAMINE; HORSERADISH PEROXIDASE; SULPIRIDE;

ARTICLE; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY; METABOLISM; MUTATION; PROTEIN BINDING; RADIOASSAY; RAT; TIME;

ANIMALS; ARRESTIN; CELL LINE; CYCLIC AMP; DOPAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUTATHIONE TRANSFERASE; GTP-BINDING PROTEINS; HORSERADISH PEROXIDASE; HUMANS; KIDNEY; MUTATION; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SULPIRIDE; TIME FACTORS; TRANSFECTION;

EID: 58849164925     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.050534     Document Type: Article

References (49)

1. Arora KK, Sakai A, and Catt KJ (1995) Effects of second intracellular loop mutations on signal transduction and internalization of the gonadotropin-releasing hormone receptor. J Biol Chem 270:22820- 22826.
2. 2-adrenergic receptor sequestration. J Biol Chem 269:2790-2795.
3. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2005) An Aktβ-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273.
4. Boll W, Ohno H, Songyang Z, Rapoport I, Cantley LC, Bonifacino JS, and Kirchhausen T (1996) Sequence requirements for the recognition of tyrosine-based endocytic signals by clathrin Ap-2 complexes. EMBO J 15:5789-5795.
5. Cen B, Xiong Y, Ma L, and Pei G (2001) Direct and differential interaction of /3-arrestins with the intracellular domains of different opioid receptors. Mol Pharmacol 59:758-764.
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099 -3108.
7. Collins BM, McCoy AJ, Kent HM, Evans PR, and Owen DJ (2002) Molecular architecture and functionalmodel oftheendocyticAP2 complex. Cell 109:523-535.
8. 2-adrenergic receptors determines subtype specificity of arrestin interaction. J Biol Chem 277:43247-43252.
9. Ferguson SSG (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
10. 2-adrenergic receptor is involved in receptor internalization. Proc Natl Acad SciUSA 94:12285-12290.
11. 2Areceptor:the third intracellularloop is α-helical and binds purified arrestins. J Neurochem 72:2206 -2214.
12. Gesty-PalmerD, ChenM, ReiterE, AhnS, Nelson CD, WangS, EckhardtAE, Cowan CL, Spurney RF, Luttrell LM, et al. (2006) Distinct β-arrestin- and G protein- dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864.
13. Gurevich EV, Benovic JL, and Gurevich VV (2004) Arrestin2 expression selectively increases during neural differentiation. J Neurochem 91:1404-1416.
14. 2-adrenergic, and m2 muscarinic cholinergic receptors. J Biol Chem 270:720-731.
15. Gurevich VV and Gurevich EV (2004) The molecular acrobatics of arrestin activation. Trends in Pharmacological Sciences 25:105-111.
16. Gurevich VV and Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465-502.
17. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, and Schubert C (2001) Crystal structure of β-arrestin at 1.9 Å: possible mechanism of receptor binding and membrane translocation. Struct Fold Des 9:869 -880.
18. Huttenrauch F, Nitzki A, Lin FT, Höning S, and Oppermann M (2002) β-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. J Biol Chem 277:30769 -30777.
19. 2 receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 49:560 -566.
20. 3 receptors by G protein-coupled receptor kinases and β -arrestins. J Biol Chem 276:37409 -37414.
21. 1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J Biol Chem 279:7999-8010.
22. Kishi H, Krishnamurthy H, Galet C, Bhaskaran RS, and Ascoli M (2002) Identification of a short linear sequence presentin the C-terminal tail of the rat follitropin receptor that modulates arrestin-3 binding in a phosphorylation-independent fashion. J Biol Chem 277:21939-21946.
23. 3 receptors. Mol Pharmacol 75:19-26.
24. 2 muscarinic acetylcholine receptor is precluded by an inhibitory element in the third intracellular loop of the receptor. J Biol Chem 275:9284-9289.
25. Liu P, Roush ED, Bruno J, Osawa S, and Weiss ER (2004) Direct binding of visual arrestin to a rhodopsin carboxyl terminal synthetic phosphopeptide. Mol Vis 10: 712-719.
26. 2 receptor enhances receptor signaling. J Recept Signal Transduct Res 27:47-65.
27. 2 adrenergic receptor Src protein kinase complexes. Science 283:655-661.
28. Macey TA, Gurevich VV, and Neve KA (2004) Preferential interaction between the dopamine D2 receptor and arrestin2 in neostriatal neurons. Mol Pharmacol 66: 1635-1642.
29. Macey TA, Liu Y, Gurevich VV, and Neve KA (2005) Dopamine D1 receptor interaction with arrestin3 in neostriatal neurons. J Neurochem 93:128-134.
30. Makarova O, Kamberov E, and Margolis B (2000) Generation of deletion and point mutations with one primer in a single cloning step. Biotechniques 29:970 -972.
31. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, and Lefkowitz RJ (2000) β -Arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290:1574-1577.
32. Moro O, Shockley MS, Lameh J, and Sadee W (1994) Overlapping multi-site domains of the muscarinic cholinergic Hm1 receptor involved in signal transduction and sequestration. J Biol Chem 269:6651-6655.
33. Mukherjee S, Gurevich VV, Preninger A, Hamm HE, Bader MF, Fazleabas AT, Birnbaumer L, and Hunzicker-Dunn M (2002) Aspartic acid 564 in the third
34. cytoplasmic loop of the luteinizing hormone/choriogonadotropin receptor is crucial for phosphorylation-independent interaction with arrestin2. J Biol Chem 277: 17916-17927.
35. 2 dopamine receptor. J Biol Chem 279: 49533-49541.
36. Neve KA, Henningsen RA, Bunzow JR, and Civelli O (1989) Functional characterization of a rat dopamine D-2 receptor cDNA expressed in a mammalian cell line. Mol Pharmacol 36:446-451.
37. Neve KA, Seamans JK, and Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
38. Ohno H, Stewart J, Fournier MC, Bosshart H, Rhee I, Miyatake S, Saito T, Gallusser A, Kirchhausen T, and Bonifacino JS (1995) Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 269:1872-1875.
39. Owen DJ and Evans PR (1998) A structural explanation for the recognition of tyrosine-based endocytotic signals. Science 282:1327-1332.
40. Pierce KL and Lefkowitz RJ (2001) Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2:727-733.
41. Qian H, Pipolo L, and Thomas WG (2001) Association of β-arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization. Mol Endocrinol 15:1706-1719.
42. Raehal KM, Walker JK, and Bohn LM (2005) Morphine side effects in β-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195-1201.
43. Raman D, Osawa S, and Weiss ER (1999) Binding of arrestin to cytoplasmic loop mutants of bovine rhodopsin. Biochemistry 38:5117-5123.
44. Royle SJ, Qureshi OS, Bobanović LK, Evans PR, Owen DJ, and Murrell-Lagnado RD (2005) Non-canonical YXXGφ endocytic motifs: recognition by AP2 and preferential utilization in P2X4 receptors. J Cell Sci 118:3073-3080.
45. Vogt C, Eickmann M, Diederich S, Moll M, and Maisner A (2005) Endocytosis of the Nipah virus glycoproteins. J Virol 79:3865-3872.
46. 2 dopamine receptors. Mol Pharmacol 50:966-976.
47. 3 dopamine receptors. Mol Pharmacol 52:181-186.
48. o by dopamine receptors in NS20Y neuroblastoma cells. J Neurosci 18:8692-8699.
49. 2- adrenergic receptors. J Biol Chem 272:17836-17842.